Date: 2014-02-17
Type of information: Company acquisition
Acquired company: CoStim Pharmaceuticals (USA)
Acquiring company: Novartis (Switzerland)
Amount: undisclosed
Terms: * On
February 17, 2014, Novartis has announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer. Already leading in cancer immunotherapy, with investigative chimeric antigen receptor (CAR) technology being developed in collaboration with the
University of Pennsylvania, with this acquisition Novartis is adding late discovery stage immunotherapy programs directed to several targets, including PD-1. These medicines could benefit patients by circumventing cancer's ability to develop resistance against current single drugs.
Details:
Related: Cancer - Oncology
Is general: Yes